Get the Stockscreener App
1.21
1.63%
-0.02
Werewolf Therapeutics Inc Stock (HOWL) Latest News
Werewolf Therapeutics Faces Geopolitical Risks Amid Changing Trade Policies with China - TipRanks
Werewolf Therapeutics Reports 2024 Financial Results and Progress - TipRanks
Werewolf Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update - GlobeNewswire
Werewolf Therapeutics reports Q4 EPS (46c), consensus (31c) - TipRanks
Werewolf Therapeutics, Inc. SEC 10-K Report - TradingView
Werewolf Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides ... - The Bakersfield Californian
Werewolf Therapeutics to Present at the 2025 Leerink Partners Global Biopharma Conference - GlobeNewswire
What Will Werewolf Therapeutics Reveal at the Leerink Biopharma Conference Next Month? - StockTitan
Werewolf Therapeutics, Inc. Announces Board Changes and Committee Appointment - Marketscreener.com
Werewolf Therapeutics (HOWL) Expected to Announce Quarterly Earnings on Thursday - MarketBeat
Werewolf Therapeutics stock hits 52-week low at $1.25 By Investing.com - Investing.com Canada
Werewolf Therapeutics stock hits 52-week low at $1.25 - Investing.com
Werewolf Therapeutics Announces Board Resignation and New Appointment - Defense World
Werewolf Therapeutics Appoints Anil Singhal, Ph.D., to its Board of Directors - GlobeNewswire
Werewolf Therapeutics appoints new board member By Investing.com - Investing.com South Africa
Werewolf Therapeutics appoints new board member - Investing.com India
Can This Oncology Pioneer Transform Werewolf's Cancer-Fighting Platform? - StockTitan
Werewolf Therapeutics Appoints Anil Singhal to Board - TipRanks
Oramed Pharmaceuticals And 2 Other US Penny Stocks To Watch - Simply Wall St
Arvinas, Inc. (ARVN) Reports Q4 Loss, Misses Revenue Estimates - Yahoo Finance
Werewolf Therapeutics, Inc. (NASDAQ:HOWL) Short Interest Update - MarketBeat
Harmony Biosciences (NASDAQ:HRMY) vs. Werewolf Therapeutics (NASDAQ:HOWL) Head to Head Review - Defense World
Barclays PLC Increases Stake in Werewolf Therapeutics, Inc. (NASDAQ:HOWL) - Defense World
Werewolf Therapeutics, Inc. (NASDAQ:HOWL) Short Interest Up 13.2% in December - MarketBeat
Jane Street Group LLC Trims Holdings in Werewolf Therapeutics, Inc. (NASDAQ:HOWL) - Defense World
Werewolf Therapeutics' SWOT analysis: stock faces challenges amid pipeline progress - Investing.com
Werewolf Therapeutics (NASDAQ:HOWL) Price Target Lowered to $4.00 at JMP Securities - MarketBeat
JMP Securities Cuts Price Target for Werewolf Therapeutics (NASDAQ:HOWL) to $4.00/Share, Down from $12.00 - HPBL
Werewolf Therapeutics provides business update, highlights 2025 outlook - Yahoo Finance
Werewolf Therapeutics Provides Business Update - citybiz
Werewolf Therapeutics Provides Business Update and Highlights 2025 Strategic Outlook - GlobeNewswire
Werewolf Therapeutics Unveils Ambitious 2025 Pipeline Plans for Cancer Immunotherapy Programs - StockTitan
Werewolf Therapeutics, Inc. (NASDAQ:HOWL) Shares Acquired by Geode Capital Management LLC - Defense World
Barclays PLC Buys 30,990 Shares of Werewolf Therapeutics, Inc. (NASDAQ:HOWL) - Defense World
State Street Corp Has $1.01 Million Position in Werewolf Therapeutics, Inc. (NASDAQ:HOWL) - Defense World
Werewolf Therapeutics, Inc. (NASDAQ:HOWL) Short Interest Up 23.6% in December - MarketBeat
Werewolf Therapeutics stock hits 52-week low at $1.58 By Investing.com - Investing.com UK
Short Interest in Werewolf Therapeutics, Inc. (NASDAQ:HOWL) Drops By 6.1% - Defense World
Short Interest in Werewolf Therapeutics, Inc. (NASDAQ:HOWL) Declines By 6.1% - MarketBeat
Werewolf Therapeutics' SWOT analysis: oncology stock's potential amid clinical trials - Investing.com Australia
HC Wainwright Reaffirms “Buy” Rating for Werewolf Therapeutics (NASDAQ:HOWL) - Defense World
Werewolf Therapeutics to Participate in the 7th Annual Evercore ISI HealthCONx Healthcare Conference - The Manila Times
Werewolf Therapeutics stock hits 52-week low at $1.62 - Investing.com India
1.39%
0.55%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):